23.03.2013 Views

White Guide and Orange Guide Formatting Project - Pfizer

White Guide and Orange Guide Formatting Project - Pfizer

White Guide and Orange Guide Formatting Project - Pfizer

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Orange</strong> <strong>Guide</strong> – Chapter 8: Privacy: Protecting Personal Information<br />

operation is hired to send the approved information to patients, an approved <strong>Pfizer</strong> Authorization for<br />

Mailing must be signed by the health plan or pharmacy to ensure compliance with these principles.<br />

All materials sent to patients must be approved by the appropriate <strong>Pfizer</strong> Review Committee (RC),<br />

which will consider potential issues of patient privacy <strong>and</strong> patient consent as part of its review process.<br />

Chart Reviews<br />

Q. Is it permissible to conduct chart reviews as part of our collaborative<br />

studies/programs with customers? If I sign a Business Associate Agreement,<br />

would that make it allowable?<br />

A. No. It is <strong>Pfizer</strong> policy that colleagues should never conduct a chart review. In<br />

addition, as discussed earlier, <strong>Pfizer</strong> is not a Business Associate of an HCP <strong>and</strong>,<br />

therefore, field-based colleagues must not sign Business Associate Agreements<br />

under any circumstance.<br />

Consumer Health Fairs <strong>and</strong> Screenings<br />

Consumer health fairs <strong>and</strong> screenings may raise patient privacy concerns since Personal Information is<br />

often obtained in the presence of sales representatives or other <strong>Pfizer</strong> colleagues attending the health<br />

fair. <strong>Pfizer</strong> Colleagues should not engage health fair attendees in discussions regarding their specific<br />

health status, symptoms, diagnosis or treatment. These discussions should occur between the patient<br />

<strong>and</strong> an appropriate HCP. Should a patient attempt to initiate such a discussion, the <strong>Pfizer</strong> colleague<br />

should make clear that he or she is not an HCP, is not providing medical advice, <strong>and</strong> should redirect the<br />

patient to an HCP at the fair or to his or her physician.<br />

Interaction with Consumers at Health Screenings by <strong>Pfizer</strong> Colleagues with Medical Background<br />

Q. May a colleague with a medical background counsel consumers on how to<br />

interpret their screening results at a <strong>Pfizer</strong>-sponsored health screening?<br />

A. No. <strong>Pfizer</strong> colleagues are not permitted to counsel patients about screening<br />

results, regardless of their education background or experience. The patient<br />

should be referred to his or her HCP.<br />

144<br />

Rev. 09/12<br />

Page 11 of 18

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!